Severe renal and pancreatic toxicities associated with ipilimumab and nivolumab combination therapy in non-small cell lung cancer: a pharmacovigilance analysis of the FDA adverse event reporting system - Report - MDSpire
Advertisement
Severe renal and pancreatic toxicities associated with ipilimumab and nivolumab combination therapy in non-small cell lung cancer: a pharmacovigilance analysis of the FDA adverse event reporting system
Severe renal and pancreatic adverse effects linked to ipilimumab and nivolumab
Overview
This study identifies significant renal and pancreatic toxicities associated with ipilimumab and nivolumab combination therapy in non-small cell lung cancer (NSCLC) patients. The findings highlight the need for enhanced monitoring strategies due to the distinct immunological mechanisms involved.
Background
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality, with immune checkpoint inhibitors (ICIs) like ipilimumab and nivolumab becoming standard treatments. While these therapies improve survival, they are associated with a range of immune-related adverse events, particularly renal and pancreatic toxicities, which may be underrecognized in clinical practice.
Data Highlights
Adverse Event
Reporting Odds Ratio (ROR)
Information Component (IC)
Glomerulonephritis Minimal Lesion
78.62
2.096
Nephrotic Syndrome
37.25
1.914
Glomerulosclerosis
61.79
2.015
Nephritis
24.99
1.832
Renal Failure
2.99
0.499
Pancreatic Toxicity
61.79
2.015
Key Findings
Combination therapy (Ipi+Nivo) shows significant signals for glomerular-predominant renal injuries.
Median time-to-onset for renal events was 73 days and for pancreatic events was 84 days in the combination group.
Co-reported renal and pancreatic events were infrequent, with serious outcomes prevalent in both treatment groups.
Renal events included nephritis and renal failure, with notable reporting odds ratios indicating increased risk.
Pancreatic toxicity signals were strong, suggesting distinct immunological mechanisms at play.
Clinical Implications
Clinicians should maintain heightened vigilance for renal and pancreatic toxicities in patients receiving Ipi+Nivo therapy. Tailored monitoring strategies beyond conventional acute interstitial nephritis surveillance are recommended to ensure timely recognition and management of these adverse events.
Conclusion
The findings underscore the need for increased awareness and monitoring of renal and pancreatic toxicities associated with ipilimumab and nivolumab combination therapy in NSCLC patients. Enhanced clinical vigilance is essential to mitigate the risks of severe adverse events.
